Abstract
Idiopathic pulmonary fibrosis (IPF) is a severe disease with an unfavorable prognosis, requiring a comprehensive, multidisciplinary approach to diagnosis and treatment. Its clinical presentation is dominated by nonspecific symptoms, primarily progressive dyspnea and cough, which clinicians may attribute to similar conditions (COPD, CHF, and others), thereby delaying verification of the diagnosis. Early diagnosis and the timely initiation of targeted therapy are crucial for improving patient outcomes. Antifibrotic medications (pirfenidone and nintedanib) are essential in IPF treatment, slowing pulmonary function decline and improving survival, particularly when initiated early. They exhibit comparable safety and efficacy profiles.

This publication has 11 references indexed in Scilit: